Is Bausch + Lomb Corporation (BLCO) a Buy, Sell, or Hold?
NYSE : BLCO
Bausch + Lomb Corporation
$16.26 USD
-$0.55 (-3.27%)
- Volume
- 276.71K
- Average Volume
- 456.76K
- Market Capitalization
- $5.8B
- P/E Ratio
- -26.27
- Dividend Yield
- 0.00%
- Price Target
- $18.50
- Year High
- $18.92
- Year Low
- $13.09
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $1.53
Company Overview
NYSE
Brenton L. Saunders
Medical - Instruments & Supplies
Healthcare
BLCO
13000
CA
USD
Liquidity Metrics
0.79
1.53
0.99
0.15
0.00
Sales & Valuation
$5.1B
1.11
0.91
1339.09
0.01
Profitability
-$1.02
-$360M
-4.21%
-3.86%
-3.41%
-1.59%
P/E Metrics
-26.27
-0.99
-0.99
Analyst Price Target & Rating
$18.50
$21.00
$16.00
1/5
16 Analysts
-12.11%
Poll Results
About Bausch + Lomb Corporation (NYSE:BLCO) Stock
Bausch + Lomb Corporation is a leading global eye health company. Its operations are structured across three primary segments: Vision Care/Consumer Health, Ophthalmic Pharmaceuticals, and Surgical. The Vision Care/Consumer Health division offers a comprehensive portfolio of contact lenses, encompassing all wearing modalities from daily disposables to frequently replaced options. This segment also provides essential contact lens care products, over-the-counter eye drops, and nutritional supplements aimed at alleviating common eye conditions like allergies, conjunctivitis, and dry eye. Through its Ophthalmic Pharmaceuticals segment, the company develops and markets both proprietary and generic prescription medications. These pharmaceuticals are utilized for post-operative recovery and the tr ... eatment of various ocular diseases, such as glaucoma, ocular hypertension, and retinal disorders. Additionally, it supplies therapeutic contact lenses. The Surgical segment is dedicated to providing advanced tools and technologies for surgical interventions related to cataracts, as well as vitreous and retinal conditions. Its offerings include intraocular lenses (IOLs) with their delivery systems, phacoemulsification equipment, and a range of other specialized surgical instruments and devices. Founded in 1853, Bausch + Lomb is headquartered in Vaughan, Canada.
Bausch + Lomb Launches EyeGility™ Inserter Preloaded IOL Delivery System in the United States
2026-07-16 07:00:00
VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced the U.S. launch of the EyeGility™ Inserter preloaded IOL delivery system. “The enVista IOL platform has long been appreciated by surgeons for its glistening-free optic and differentiated optic portfolio to suit a wide range of patients,” said Wayne Caulder, vice president and general manager, North America Surgi.
Bausch + Lomb Announces Phase 2 Results for Glaucoma Neuroprotective Candidate
2026-07-09 16:30:00
VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced topline results from its Phase 2 study evaluating BL1107 in patients with glaucoma. The study did not achieve its primary endpoint of replicating visual function improvements observed in a smaller Phase 1/2a study following 28 days of topical administration. Based on the totality of the data, the company has dec.
2026-07-09 07:00:00
VAUGHAN, Ontario, & MENLO PARK, Calif.--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced the creation of Orphia™, a new AI-powered digital health platform built on the belief that eye care providers should spend less time managing disconnected tools and technologies and more time caring for patients. The platform is brand agnostic and designed to serve all eye care providers, r.
Bausch + Lomb Will Release Second-Quarter 2026 Financial Results on July 29
2026-07-06 07:15:00
VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, will release its second-quarter financial results on Wednesday, July 29, 2026. The company will host a conference call and live webcast at 8 a.m. ET to discuss the results and provide a business update. All materials will be made available on the Investor Relations section of the Bausch + Lomb website prior to the start of the.
2026-07-01 07:00:00
VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced new findings from its third annual State of Dry Eye survey, which reveals that the impact of dry eye can extend beyond the burden of physical symptoms, affecting how patients view their emotional health and wellbeing. This year's survey was conducted online by The Harris Poll in May 2026 among 1,000 dry eye suff.
2026-06-09 19:32:10
Bausch + Lomb Corporation (BLCO) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
2026-06-01 17:44:04
Bausch + Lomb Corporation (BLCO) Discusses Project Halo and Myopia Control Developments in Vision Care Transcript
Bausch + Lomb Launches Blink® Triple Care Preservative Free Lubricant Eye Drops in the United States
2026-06-01 06:59:00
VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced the U.S. launch of Blink Triple Care Preservative Free eye drops, which provide instant, long-lasting relief for dry eyes without the use of preservatives and are packaged in a multi-dose bottle. Blink Triple Care Preservative Free is made with the same clinically proven formula as Blink Triple Care, helping red.
Frequently Asked Questions
-
What is the current Bausch + Lomb Corporation (BLCO) stock price?
-
Bausch + Lomb Corporation(NYSE:BLCO) stock price is $16.26 in the last trading session. During the trading session, BLCO stock reached the peak price of $18.915 while $13.09 was the lowest point it dropped to. The percentage change in BLCO stock occurred in the recent session was --3.27% while the dollar amount for the price change in BLCO stock was -$0.55.
-
BLCO's industry and sector of operation?
-
The NYSE listed BLCO is part of Medical - Instruments & Supplies industry that operates in the broader Healthcare sector.
-
Who are the executives of BLCO?
-
Alan Waterhouse CPFA | Executive Vice President and Chief Supply Chain & Operations Officer
Andrew Stewart | President of Global Pharmaceuticals & International Consumer
A. Robert D. Bailey | Executive Vice President & Chief Legal Officer
George Gadkowski | Vice President & Head of Investor Relations & Business Insights
Jonathon L. Kellerman | Chief Compliance Officer -
How many employees does BLCO have?
-
Number of BLCO employees currently stands at 13000. BLCO operates from 520 Applewood Crescent, Vaughan, ON L4K 4B4, CA.
-
Link for BLCO official website?
-
Official Website of BLCO is: https://www.bausch.com
-
How do I contact BLCO?
-
BLCO could be contacted at phone #905 695 7700 and can also be accessed through its website. BLCO operates from 520 Applewood Crescent, Vaughan, ON L4K 4B4, CA.
-
How many shares of BLCO are traded daily?
-
The average number of BLCO shares traded daily for last 3 months was 456.76K.
-
What is the market cap of BLCO currently?
-
The market value of BLCO currently stands at $5.8B with its latest stock price at $16.26